Exon 8 amplification of epidermal growth factor receptor (EGFR) in invasive breast carcinomas

Souka E, Alexiadis E, Theohari I, Giannopoulou I, Papadimitriou C & Nakopoulou L 
(2012) Histopathology 61, 644–651 Exon 8 amplification of epidermal growth factor receptor (EGFR) in invasive breast carcinomas Aims:  The rate of EGFR amplification in breast cancer ranges between 0% and 15%. Rece...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Histopathology 2012-10, Vol.61 (4), p.644-651
Hauptverfasser: Souka, Efthimia, Alexiadis, Evaggelos, Theohari, Irini, Giannopoulou, Ioanna, Papadimitriou, Christos, Nakopoulou, Lydia
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Souka E, Alexiadis E, Theohari I, Giannopoulou I, Papadimitriou C & Nakopoulou L 
(2012) Histopathology 61, 644–651 Exon 8 amplification of epidermal growth factor receptor (EGFR) in invasive breast carcinomas Aims:  The rate of EGFR amplification in breast cancer ranges between 0% and 15%. Recent studies have focused on the amplification status of cytosine–adenine (CA) repeats in intron 1 of the gene and correlated it with increased EGFR protein. The aim of this study was to investigate, for the first time, the significance of coding exon 8 amplification of EGFR in invasive breast cancer. Methods and results:  We investigated, by means of real‐time polymerase chain reaction (PCR), the amplification status of exon 8 of the EGFR gene in 148 paraffin‐embedded tissue sections, 115 with invasive breast carcinoma and 33 controls. Immunohistochemistry was utilized to detect EGFR and human epidermal growth factor receptor 2 (HER2) expression. Univariate and multivariate statistical analyses were performed for the evaluation of our results. EGFR amplification was observed in 7.8% of the patients, and EGFR was immunodetected in 9.6%. EGFR amplification was correlated positively with EGFR expression (P 
ISSN:0309-0167
1365-2559
DOI:10.1111/j.1365-2559.2012.04315.x